p.62 抽出テキスト

tion in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol 2018; 314: H1033-H1042. PMID: 29424571 122. Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018; 39: 3439- 3450. PMID: 30165580 123. Allan T, Dryer K, Fearon WF, et al. Coronary microvascular dysfunction and clinical outcomes in patients with heart failure with preserved ejection fraction. J Card Fail 2019; 25: 843-845. PMID: 31487534 124. D’Amario D, Migliaro S, Borovac JA, et al. Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol 2019; 10: 1347. PMID: 31749710 125. Tromp J, Hage C, Ouwerkerk W, et al. Biomarker correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Circulation 2019; 140: 1359-1361. PMID: 31609659 126. Ahmad A, Corban MT, Toya T, et al. Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. Eur J Heart Fail 2021; 23: 765-772. PMID: 32949186 127. Hage C, Svedlund S, Saraste A, et al. Association of coronary microvascular dysfunction with heart failure hospitalizations and mortality in heart failure with preserved ejection fraction: A follow-up in the PROMIS-HFpEF Study. J Card Fail 2020; 26: 1016-1021. PMID: 32846205 128. Miller VM. Universality of sex differences in cardiovascular outcomes: where do we go from here? Eur Heart J 2020; 41: 1697-1699. PMID: 32357237 129. Suhrs HE, Schroder J, Bové KB, et al. Inflammation, non-endothelial dependent coronary microvascular function and diastolic function Are they linked? PLoS One 2020; 15: e0236035. PMID: 32673354 130. Yang JH, Obokata M, Reddy YNV, et al. Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail 2020; 22: 432-441. PMID: 31840366 131. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007; 356: 830-840. PMID: 17314342 132. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J 2014; 35: 1101-1111. PMID: 24366916 133. Camici PG, d’Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol 2015; 12: 48-62. PMID: 25311229 134. Godo S, Suda A, Takahashi J, et al. Coronary microvascular dysfunction. Arterioscler Thromb Vasc Biol 2021; 41: 1625-1637. PMID: 33761763 135. Godo S, Takahashi J, Yasuda S, et al. Endothelium in coronary macrovascular and microvascular diseases. J Cardiovasc Pharmacol 2021; 78 Suppl: S19-S29. PMID: 34840261 136. Shimokawa H. Coronary vasomotion abnormalities. Springer Singapore, 2021: 1-155. 137. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J 2014; 78: 2779-2801. PMID: 25273915 138. Aldiwani H, Mahdai S, Alhatemi G, et al. Microvascular angina: diagnosis and management. Eur Cardiol 2021; 16: e46. PMID: 34950242 139. Takahashi J, Suda A, Nishimiya K, et al. Pathophysiology and diagnosis of coronary functional abnormalities. Eur Cardiol 2021; 16: e30. PMID: 34603510 140. Mileva N, Nagumo S, Mizukami T, et al. Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis. J Am Heart Assoc 2022; 11: e023207. PMID: 35301851 141. Lee BK, Lim HS, Fearon WF, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation 2015; 131: 1054-1060. PMID: 25712205 142. Ford TJ, Yii E, Sidik N, et al. Ischemia and no obstructive coronary artery disease: Prevalence and correlates of coronary vasomotion disorders. Circ Cardiovasc Interv 2019; 12: e008126. PMID: 31833416 143. Suda A, Takahashi J, Hao K, et al. Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease. J Am Coll Cardiol 2019; 74: 2350-2360. PMID: 31699275 144. Ohura-Kajitani S, Shiroto T, Godo S, et al. Marked impairment of endothelium-dependent digital vasodilatations in patients with microvascular angina: Evidence for systemic small artery disease. Arterioscler Thromb Vasc Biol 2020; 40: 1400-1412. PMID: 32237907 145. Yamanaga K, Tsujita K, Komura N, et al. Single-wire pressure and

flow velocity measurement for quantifying microvascular dysfunction in patients with coronary vasospastic angina. Am J Physiol Heart Circ Physiol 2015; 308: H478-H484. PMID: 25527779 146. Teragawa H, Oshita C, Uchimura Y, et al. Coronary microvascular

vasodilatory function: Related clinical features and differences according to the different coronary arteries and types of coronary spasm. J Clin Med 2021; 11:  130. PMID: 35011869 147. Yamagishi M, Ito K, Tsutsui H, et al. Lesion severity and hypercholesterolemia determine long-term prognosis of vasospastic angina treated with calcium channel antagonists. Circ J 2003; 67: 1029- 1035. PMID: 14639019 148. Khuddus MA, Pepine CJ, Handberg EM, et al. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: A substudy from the National Heart, Lung and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Interv Cardiol 2010; 23: 511-519. PMID: 21029178 149. Takagi Y, Takahashi J, Yasuda S, et al. Prognostic stratification of patients with vasospastic angina: A comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. J Am Coll Cardiol 2013; 62: 1144-1153. PMID: 23916938 150. Ishii M, Kaikita K, Sato K, et al. Acetylcholine-provoked coronary spasm at site of significant organic stenosis predicts poor prognosis in patients with coronary vasospastic angina. J Am Coll Cardiol 2015; 66: 1105-1115. PMID: 26337988 151. Ishii M, Kaikita K, Sato K, et al. Changes in the risk factors for coronary spasm. Int J Cardiol Heart Vasc 2016; 12: 85-87. PMID: 28616549 152. Godo S, Corban MT, Toya T, et al. Association of coronary microvascular endothelial dysfunction with vulnerable plaque characteristics in early coronary atherosclerosis. EuroIntervention 2020; 16: 387- 394. PMID: 31403459 153. Pepine CJ, Ferdinand KC, Shaw LJ, et al. Emergence of nonobstructive coronary artery disease: A woman’s problem and need for change in definition on angiography. J Am Coll Cardiol 2015; 66: 1918-1933. PMID: 26493665 154. Eskerud I, Gerdts E, Larsen TH, et al. Total coronary atherosclerotic plaque burden is associated with myocardial ischemia in non-obstructive coronary artery disease. Int J Cardiol Heart Vasc 2021; 35: 100831. PMID: 34258383 155. Mehta PK, Quesada O, Al-Badri A, et al. Ischemia and no obstructive coronary arteries in patients with stable ischemic heart disease. Int J Cardiol 2022; 348: 1-8. PMID: 34902504 156. Wei J, Mehta PK, Johnson BD, et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: Results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Interv 2012; 5: 646-653. PMID: 22721660 157. Takagi Y, Yasuda S, Takahashi J, et al. Clinical implications of provocation tests for coronary artery spasm: safety, arrhythmic complications, and prognostic impact: multicentre registry study of the Japanese Coronary Spasm Association. Eur Heart J 2013; 34: 258-267. PMID: 22782943 158. Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation 2014; 129: 1723- 1730. PMID: 24573349 159. Reriani M, Sara JD, Flammer AJ, et al. Coronary endothelial function testing provides superior discrimination compared with standard clinical risk scoring in prediction of cardiovascular events. Coron Artery Dis 2016; 27: 213-220. PMID: 26882018 160. Hao K, Takahashi J, Kikuchi Y, et al. Prognostic impacts of comorbid significant coronary stenosis and coronary artery spasm in patients with stable coronary artery disease. J Am Heart Assoc 2021; 10: e017831. PMID: 33455423 161. Konst RE, Damman P, Pellegrini D, et al. Diagnostic approach in patients with angina and no obstructive coronary artery disease: emphasising the role of the coronary function test. Neth Heart J 2021; 29: 121-128. PMID: 33415605 162. Heggie R, Briggs A, Stanley B, et al. Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial. Int J Cardiol 2021; 337: 44-51. PMID: 33992700 163. Feenstra RGT, Seitz A, Boerhout CKM, et al. Principles and pitfalls in coronary vasomotor function testing. EuroIntervention 2022; 17: 1271-1280. PMID: 34278990 164. Morrow AJ, Ford TJ, Mangion K, et al. Rationale and design of the

Medical Research Council’s Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial. Am Heart J 2020; 229: 70-80. PMID: 32942043